- Home
- NYXH vs BNTC Comparison
NYXH vs BNTC Comparison
Compare NYXH & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- BNTC
- Stock Information
- Founded
- NYXH 2009
- BNTC 1995
- Country
- NYXH Belgium
- BNTC United States
- Employees
- NYXH N/A
- BNTC N/A
- Industry
- NYXH Medical/Dental Instruments
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- NYXH Health Care
- BNTC Health Care
- Exchange
- NYXH Nasdaq
- BNTC Nasdaq
- Market Cap
- NYXH 273.3M
- BNTC 335.5M
- IPO Year
- NYXH 2021
- BNTC N/A
- Fundamental
- Price
- NYXH $7.46
- BNTC $11.53
- Analyst Decision
- NYXH Strong Buy
- BNTC Strong Buy
- Analyst Count
- NYXH 4
- BNTC 5
- Target Price
- NYXH $14.50
- BNTC $26.00
- AVG Volume (30 Days)
- NYXH 49.7K
- BNTC 75.3K
- Earning Date
- NYXH 08-18-2025
- BNTC 09-25-2025
- Dividend Yield
- NYXH N/A
- BNTC N/A
- EPS Growth
- NYXH N/A
- BNTC N/A
- EPS
- NYXH N/A
- BNTC N/A
- Revenue
- NYXH $4,716,818.00
- BNTC N/A
- Revenue This Year
- NYXH $209.22
- BNTC N/A
- Revenue Next Year
- NYXH $219.37
- BNTC N/A
- P/E Ratio
- NYXH N/A
- BNTC N/A
- Revenue Growth
- NYXH N/A
- BNTC N/A
- 52 Week Low
- NYXH $5.55
- BNTC $7.05
- 52 Week High
- NYXH $11.87
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- NYXH 46.80
- BNTC 44.40
- Support Level
- NYXH $6.90
- BNTC $10.53
- Resistance Level
- NYXH $7.60
- BNTC $11.74
- Average True Range (ATR)
- NYXH 0.34
- BNTC 0.70
- MACD
- NYXH -0.05
- BNTC 0.08
- Stochastic Oscillator
- NYXH 38.10
- BNTC 57.64
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.